Biopharmaceutical company developing therapies for oncology and other diseases.
Zevra Therapeutics, Inc. is a pioneering biopharmaceutical company dedicated to the discovery and development of proprietary prodrugs aimed at treating severe medical conditions across the United States. Leveraging its innovative Ligand Activated Therapy platform, the company focuses on transforming therapeutic approaches through advanced drug delivery systems.
At the forefront of its pipeline is KP1077, a promising lead product candidate designed to address idiopathic hypersomnia and narcolepsy. KP1077 is currently progressing through Phase 2 and Phase 1/2 clinical trials, respectively, demonstrating Zevra Therapeutics' commitment to addressing unmet needs in sleep disorders.
Additionally, Zevra Therapeutics is advancing Celiprolol, another innovative prodrug candidate undergoing Phase 1/2 clinical trials for the treatment of vascular Ehlers Danlos syndrome, a rare genetic disorder affecting connective tissues.
Beyond its developmental pipeline, Zevra Therapeutics markets AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older, and OLPRUVA for urea cycle disorders. The company is also actively involved in advancing Arimoclomol, a potential therapy for Niemann-Pick disease type C, through clinical development stages.
Founded in 2006 and headquartered in Celebration, Florida, Zevra Therapeutics, formerly known as KemPharm, Inc., continues to forge strategic collaborations and licensing agreements with industry leaders like Commave Therapeutics SA, Acer, and Relief Therapeutics, Inc. These partnerships underscore the company's commitment to expanding its innovative portfolio and bringing transformative therapies to patients worldwide.